跳至主要内容
临床试验/NCT02718001
NCT02718001
进行中(未招募)
不适用

Edwards EVOQUE Eos Mitral Valve Replacement: Investigation of Safety and Performance After Mitral Valve Replacement With Transcatheter Device (MISCEND)

Edwards Lifesciences29 个研究点 分布在 2 个国家目标入组 123 人2015年2月6日

概览

阶段
不适用
干预措施
Edwards EVOQUE Eos Mitral Valve Replacement System
疾病 / 适应症
Mitral Valve Regurgitation (Degenerative or Functional)
发起方
Edwards Lifesciences
入组人数
123
试验地点
29
主要终点
Composite of major adverse events
状态
进行中(未招募)
最后更新
19天前

概览

简要总结

Study to evaluate the safety and performance of the Edwards EVOQUE Eos mitral valve replacement system

详细描述

The study is a multi-center, prospective, single-arm, and non-randomized study designed to evaluate the safety and performance of the Edwards EVOQUE Eos mitral valve replacement system.

注册库
clinicaltrials.gov
开始日期
2015年2月6日
结束日期
2033年4月30日
最后更新
19天前
研究类型
Interventional
研究设计
Single Group
性别
All

研究者

发起方
Edwards Lifesciences
责任方
Sponsor

入排标准

入选标准

  • Clinically significant, symptomatic mitral regurgitation
  • High risk for open-heart surgery
  • Meets anatomical criteria

排除标准

  • Unsuitable anatomy
  • Patient is inoperable

研究组 & 干预措施

Treatment

Treatment with the Edwards EVOQUE Eos mitral valve replacement system

干预措施: Edwards EVOQUE Eos Mitral Valve Replacement System

结局指标

主要结局

Composite of major adverse events

时间窗: 30 days

Proportion of patients with major adverse events

次要结局

  • NYHA functional class(30 days, 6 Months, 12 Months, annual for five years)
  • Clinical Success(30 days)
  • Procedural Success(Discharge or 7 days post-procedure, whichever occurs first)
  • Reduction in MR grade(30 days, 6 Months, 12 Months, annual for five years)
  • Device Success(Immediately after procedure)
  • Six minute walk test(30 days, 6 Months, 12 Months, annual for five years)

研究点 (29)

Loading locations...

相似试验